Peptide Storage and Stability: How to Store Lyophilized Peptides

Short answer: store sealed vials of lyophilized (freeze-dried) peptide frozen, at about −20 °C or colder, for long-term storage, and use a refrigerator (2–8 °C) only for shorter periods. Keep vials sealed, dry and away from light, and let a cold vial reach room temperature before you open it. Each of those rules slows a specific set of chemical reactions (oxidation, deamidation, hydrolysis and aggregation), all of which run faster with heat and with water. How long a given lot stays within specification depends on its amino acid sequence, so the lot’s Certificate of Analysis and any retest date are the reference for an individual vial.

This guide covers sealed, lyophilized material. It sets out the storage conditions first and then the degradation chemistry behind them, so the reason for each rule is visible.

How should lyophilized peptides be stored?

Whatever the temperature:

• Keep it sealed. The stopper and crimp are the moisture barrier. Every opening lets in humid air.
• Keep it dry. Store vials in a closed secondary container with desiccant where possible.
• Keep it dark. A box or amber vial is enough to block room light.
• Keep it steady. Manual-defrost freezers hold temperature more evenly than frost-free units, which warm briefly during each defrost cycle.

Why a dry powder is more stable than a solution

Most peptide degradation reactions need water, either as a reactant or as a medium that lets molecules move and meet. Lyophilization removes most of it, which is why freeze-dried peptides keep far longer than solutions. It does not stop chemistry altogether. A review of solid-state stability by Lai and Topp lists deamidation, peptide-bond cleavage, oxidation, the Maillard reaction, β-elimination and dimerization or aggregation as reactions that still occur in dry proteins and peptides, governed by temperature, moisture content, excipients and whether the solid is amorphous or crystalline².

Residual moisture matters more than its small mass suggests, because water acts as a plasticizer that loosens the glassy solid. Breen and colleagues stored a lyophilized protein formulation at residual moistures of 1 to 8% and measured its glass transition temperature falling from about 80 °C at 1% moisture to 25 °C at 8%. The higher-moisture samples showed faster aspartate isomerization at elevated temperatures, while every formulation was stable at 5 °C³. Cold and dry work together, and a cold vial that picks up water loses part of the protection that cold provides.

The degradation chemistry, residue by residue

Most peptide degradation runs through a short list of residues and bonds, so a sequence tells you in advance which reactions to watch for^4,5.

Oxidation: methionine, cysteine, tryptophan, histidine, tyrosine

• Methionine is one of the most readily oxidized amino acids. Its thioether sulfur is converted to methionine sulfoxide, a mass increase of 16 Da⁶.
• Cysteine thiols oxidize to disulfides, either within one molecule (−2 Da) or between two molecules to form dimers, and existing disulfides can exchange partners⁷.
• Tryptophan, histidine and tyrosine are oxidized by light-driven and metal-catalyzed processes. Trace metals, peroxides left over from excipients and headspace oxygen all feed these reactions^8,9.

On a chromatogram, oxidation usually appears as a new peak next to the main peak. On a mass spectrum it appears as +16 Da steps. Both are explained in interpreting mass spectrometry on peptide COAs.

Deamidation: asparagine and glutamine

The side-chain amide of asparagine can attack the neighbouring backbone and close into a five-membered succinimide ring, releasing ammonia. The ring then opens to a mixture of aspartate and isoaspartate, a net mass change of only +0.98 Da. Geiger and Clarke measured a deamidation half-life of just 1.4 days at 37 °C and pH 7.4 for the model hexapeptide VYPNGA in solution, and found that replacing the glycine after the asparagine with leucine or proline slowed the reaction 33- to 50-fold¹⁰.

The residue on the carboxyl side sets the rate. Tyler-Cross and Schirch found that increasing the size and branching of that residue slowed deamidation by up to 70-fold relative to Asn-Gly, the fastest sequence, and that neutral and alkaline conditions gave isoaspartate and aspartate products in roughly a 3:1 ratio¹¹. Glutamine deamidates more slowly, through a six-membered ring. Robinson and colleagues measured 52 glutaminyl and 52 asparaginyl pentapeptides and extended a sequence-based rate model to half-times as long as 2–50 years¹².

An N-terminal glutamine can also cyclize to pyroglutamate, losing ammonia (−17 Da). Dick and colleagues found this reaction to be spontaneous and highly dependent on temperature and buffer composition in model peptides¹³.

Hydrolysis and isomerization at aspartate

Aspartate residues form the same cyclic imide intermediate as asparagine. Oliyai and Borchardt followed a model hexapeptide containing an Asp-Gly bond across pH: at strongly acidic pH the main reaction was hydrolysis of the Asp-Gly bond, which cuts the backbone; at pH 4–5 cleavage and isomerization to isoaspartate ran side by side; and above pH 6 isomerization was the only product observed¹⁴. Isoaspartate has the same mass as aspartate, so it is detected by chromatography rather than by mass. Tyler-Cross and Schirch also observed backbone cleavage at Asn-Ser bonds at about a tenth of the deamidation rate¹¹.

Aggregation and dimerization

Peptides can associate non-covalently into soluble or insoluble aggregates, or covalently through disulfide bonds. Concentration, temperature, interfaces and moisture all push the balance towards aggregation¹⁵. In the lyophilized formulation studied by Breen and colleagues, high-moisture samples stored above their glass transition temperature aggregated faster than drier ones³. Aggregates show up as late-eluting peaks, size-exclusion signals or material that will not fully dissolve.

Summary: what to look for

Moisture, light and temperature cycling

• Moisture. Lyophilized peptides are usually amorphous solids that take up water from humid air. Opening a cold vial pulls in room air, and its moisture condenses on the powder. Let the sealed vial reach room temperature first, open it for as short a time as you can, and reseal it promptly.
• Light. Kerwin and Remmele identify tryptophan, tyrosine, phenylalanine and cysteine or cystine as the residues that undergo primary photo-oxidation¹⁶. Photostability is tested to the standard conditions in ICH Q1B¹⁷. Room light during handling is not a problem. Months on a lit shelf can be.
• Temperature cycling. For a sealed dry powder, the practical risk of moving between temperatures is condensation. Freeze–thaw damage in the strict sense is a solution-state problem. As water freezes, solutes concentrate and buffer salts can crystallize. Gómez and colleagues measured 50 and 100 mM sodium phosphate buffers that started at pH 7.4 reaching about pH 4.2 at −10 °C¹⁸. Kolhe and colleagues measured pH shifts across common buffers between +25 and −30 °C¹⁹, and Cao and colleagues linked protein damage during freezing and thawing to the ice–liquid interface²⁰. A lyophilized solid that stays sealed avoids all of this.

Do peptides expire?

Lyophilized peptides degrade gradually rather than failing on a fixed date. Stability scientists separate two ideas. A retest date is the date after which a material should be examined again to confirm it still meets its specification. A shelf life is a period during which the material is expected to stay within specification under defined storage conditions¹. Both come from stability data, not from a general rule.

ICH Q1A(R2) describes how that data is generated. Stress testing exposes the material to temperatures in 10 °C steps above the accelerated condition, humidity of 75% RH or more, oxidation and light, to find out which degradation products form. Long-term and accelerated studies then follow purity over time with stability-indicating methods, meaning methods that separate those degradation products from the main peak¹.

For a peptide you hold, the practical version is short. If the vial has been stored well and is inside its retest date, the release COA is the reference. If it is past that date, or its storage history is uncertain, re-test purity with the same HPLC method and compare the chromatogram with the release result.

What the COA tells you about storage

A lot-specific Certificate of Analysis records the lot number, the test date and the purity and identity results at release. It is the baseline that any later change is measured against:

• A drop in HPLC purity, or new peaks next to the main peak, means degradation products have formed. See HPLC testing explained.
• Mass shifts of +16 Da, +0.98 Da or −17 Da, or a dimer, point to the specific reaction from the table above. See mass spectrometry on peptide COAs.
• The test date tells you how old the baseline is. See why testing dates matter.
• Results are only comparable between reports that used the same method. See how to compare COA results across batches.

Lot COAs for Peptide Titans products are in the certificate library, and the fields are explained in how to read a peptide COA. Related terms are defined in the glossary under stability, storage conditions and lyophilization.

Frequently asked questions

References

1. ICH Harmonised Tripartite Guideline. Q1A(R2): Stability Testing of New Drug Substances and Products. Step 4, 6 February 2003. ICH PDF · FDA guidance page
2. Lai MC, Topp EM. Solid-state chemical stability of proteins and peptides. J Pharm Sci. 1999;88(5):489–500. PMID 10229638
3. Breen ED, Curley JG, Overcashier DE, Hsu CC, Shire SJ. Effect of moisture on the stability of a lyophilized humanized monoclonal antibody formulation. Pharm Res. 2001;18(9):1345–1353. PMID 11683251
4. Manning MC, Patel K, Borchardt RT. Stability of protein pharmaceuticals. Pharm Res. 1989;6(11):903–918. PMID 2687836
5. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. PMID 20143256
6. Vogt W. Oxidation of methionyl residues in proteins: tools, targets, and reversal. Free Radic Biol Med. 1995;18(1):93–105. PMID 7896176
7. Trivedi MV, Laurence JS, Siahaan TJ. The role of thiols and disulfides on protein stability. Curr Protein Pept Sci. 2009;10(6):614–625. PMID 19538140
8. Li S, Schöneich C, Borchardt RT. Chemical instability of protein pharmaceuticals: mechanisms of oxidation and strategies for stabilization. Biotechnol Bioeng. 1995;48(5):490–500. PMID 18623513
9. Hovorka S, Schöneich C. Oxidative degradation of pharmaceuticals: theory, mechanisms and inhibition. J Pharm Sci. 2001;90(3):253–269. PMID 11170019
10. Geiger T, Clarke S. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. J Biol Chem. 1987;262(2):785–794. PMID 3805008
11. Tyler-Cross R, Schirch V. Effects of amino acid sequence, buffers, and ionic strength on the rate and mechanism of deamidation of asparagine residues in small peptides. J Biol Chem. 1991;266(33):22549–22556. PMID 1939272
12. Robinson NE, Robinson ZW, Robinson BR, et al. Structure-dependent nonenzymatic deamidation of glutaminyl and asparaginyl pentapeptides. J Pept Res. 2004;63(5):426–436. PMID 15140160
13. Dick LW Jr, Kim C, Qiu D, Cheng KC. Determination of the origin of the N-terminal pyro-glutamate variation in monoclonal antibodies using model peptides. Biotechnol Bioeng. 2007;97(3):544–553. PMID 17099914
14. Oliyai C, Borchardt RT. Chemical pathways of peptide degradation. IV. Pathways, kinetics, and mechanism of degradation of an aspartyl residue in a model hexapeptide. Pharm Res. 1993;10(1):95–102. PMID 8430066
15. Wang W. Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm. 2005;289(1–2):1–30. PMID 15652195
16. Kerwin BA, Remmele RL Jr. Protect from light: photodegradation and protein biologics. J Pharm Sci. 2007;96(6):1468–1479. PMID 17230445
17. ICH Harmonised Tripartite Guideline. Q1B: Photostability Testing of New Drug Substances and Products. FDA guidance page
18. Gómez G, Pikal MJ, Rodríguez-Hornedo N. Effect of initial buffer composition on pH changes during far-from-equilibrium freezing of sodium phosphate buffer solutions. Pharm Res. 2001;18(1):90–97. PMID 11336359
19. Kolhe P, Amend E, Singh SK. Impact of freezing on pH of buffered solutions and consequences for monoclonal antibody aggregation. Biotechnol Prog. 2010;26(3):727–733. PMID 20039442
20. Cao E, Chen Y, Cui Z, Foster PR. Effect of freezing and thawing rates on denaturation of proteins in aqueous solutions. Biotechnol Bioeng. 2003;82(6):684–690. PMID 12673768

Research context: This guide describes the storage and chemical stability of research materials for laboratory work. It is not guidance for any use outside qualified research.